AR129935A1 - Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos - Google Patents

Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos

Info

Publication number
AR129935A1
AR129935A1 ARP230101858A ARP230101858A AR129935A1 AR 129935 A1 AR129935 A1 AR 129935A1 AR P230101858 A ARP230101858 A AR P230101858A AR P230101858 A ARP230101858 A AR P230101858A AR 129935 A1 AR129935 A1 AR 129935A1
Authority
AR
Argentina
Prior art keywords
antibody
antigen
seq
amino acid
acid sequence
Prior art date
Application number
ARP230101858A
Other languages
English (en)
Inventor
Dong Yang
Paul H Song
Hanwen Xu
Gang Qin
Yajun - Hu Mingyu Sun
Original Assignee
Genequantum Healthcare Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2023/086107 external-priority patent/WO2024207177A1/en
Application filed by Genequantum Healthcare Suzhou Co Ltd filed Critical Genequantum Healthcare Suzhou Co Ltd
Publication of AR129935A1 publication Critical patent/AR129935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un conjugado que tiene la estructura de fórmula (3). Un anticuerpo anti-TROP2 o un fragmento de unión a antígeno del mismo, que comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), en donde la VH comprende: (i) HCDR1 que comprende la secuencia de aminoácidos de X¹AGMN, en donde X¹ es N o A; (ii) HCDR2 que comprende la secuencia de aminoácidos de WINTDSGEPTYTDDFKG (SEQ ID Nº 10) o WINTYTGEPTYTDDFKG (SEQ ID Nº 8); (iii) HCDR3 que comprende la secuencia de aminoácidos de GGFGSSYWYFDV (SEQ ID Nº 11); y/o la VL comprende: (i) LCDR1 que comprende la secuencia de aminoácidos de KASQDVSIAVA (SEQ ID Nº 13) (ii) LCDR2 que comprende la secuencia de aminoácidos de SASYRYT (SEQ ID Nº 15); (iii) LCDR3 que comprende la secuencia de aminoácidos de QQHYITPLT (SEQ ID Nº 16). Un polinucleótido o vector que comprende secuencias de ácido nucleico que codifican el anticuerpo o fragmento de unión a antígeno de cualquiera de las reivindicaciones 21 a 25. Una célula hospedadora que comprende el polinucleótido o el vector de la reivindicación 26. Una composición farmacéutica que comprende una cantidad profiláctica o terapéuticamente eficaz del conjugado de cualquiera de las reivindicaciones 1 a 20, el anticuerpo o fragmento de unión a antígeno de cualquiera de las reivindicaciones 21 a 25, el polinucleótido o vector de la reivindicación 26, o la célula hospedadora de la reivindicación 27; y al menos un portador farmacéuticamente aceptable. Un conjugado de anticuerpo de fármaco que comprende el anticuerpo de cualquiera de las reivindicaciones 21 a 25. Un método para producir el anticuerpo o fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones 21 a 25, que comprende: (i) cultivar la célula hospedadora de la reivindicación 27 en condiciones adecuadas para la expresión del anticuerpo o fragmento de unión a antígeno del mismo, y (ii) recuperar el anticuerpo o el fragmento de unión al antígeno del mismo de la célula hospedadora o el cultivo celular del mismo.
ARP230101858A 2022-07-15 2023-07-14 Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos AR129935A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022106014 2022-07-15
PCT/CN2023/086107 WO2024207177A1 (en) 2023-04-04 2023-04-04 Antibody, linkers, payload, conjugates and applications thereof
CN2023088115 2023-04-13

Publications (1)

Publication Number Publication Date
AR129935A1 true AR129935A1 (es) 2024-10-16

Family

ID=87576084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101858A AR129935A1 (es) 2022-07-15 2023-07-14 Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos

Country Status (12)

Country Link
US (1) US12539336B2 (es)
EP (1) EP4554626A2 (es)
JP (1) JP2025524725A (es)
KR (1) KR20250075560A (es)
CN (2) CN118251241B (es)
AR (1) AR129935A1 (es)
AU (1) AU2023306440A1 (es)
CA (1) CA3262069A1 (es)
IL (1) IL318296A (es)
MA (1) MA71455A (es)
MX (1) MX2025000590A (es)
WO (1) WO2024012566A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024213091A1 (en) * 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
WO2025149014A1 (en) * 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition
WO2025199464A1 (en) * 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
JPH0873461A (ja) 1994-09-06 1996-03-19 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体、その製造法および抗腫瘍剤
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2014057687A1 (ja) 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
GB2529356B (en) 2013-04-28 2020-12-23 Genequantum Healthcare Co Ltd Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
CA2920192A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
PT3088419T (pt) 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
HRP20190431T1 (hr) 2014-01-31 2019-04-19 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
EP3517114A1 (en) 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CN119241554A (zh) * 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
EP3821005A4 (en) 2018-07-09 2022-10-26 Genequantum Healthcare (Suzhou) Co., Ltd. AGAINST TROPHOBLAST ANTIGEN 2 (TROP2) SPECIFIC ANTIBODIES
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
MY209065A (en) 2018-09-30 2025-06-18 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
CN111689980A (zh) 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
AU2020347715A1 (en) 2019-09-18 2022-04-07 Systimmune, Inc. Camptothecin derivative and conjugate thereof
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
WO2021136475A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
CN114901694A (zh) 2019-12-31 2022-08-12 启德医药科技（苏州）有限公司 抗trop2抗体、抗体-药物缀合物及其应用
TWI891714B (zh) 2020-01-22 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 抗trop-2抗體-依喜替康類似物偶聯物及其醫藥用途
US20230140397A1 (en) 2020-03-25 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
WO2021190581A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
TWI904149B (zh) 2020-03-25 2025-11-11 大陸商江蘇豪森藥業集團有限公司 Ｂ７ｈ３抗體-依喜替康類似物偶聯物及其醫藥用途
JP7730836B2 (ja) 2020-03-25 2025-08-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体の調製方法
WO2021249228A1 (zh) 2020-06-08 2021-12-16 四川百利药业有限责任公司 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
JP7780953B2 (ja) 2020-09-15 2025-12-05 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン類医薬品及びその抗体複合体
CN121944137A (zh) 2020-09-30 2026-05-01 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
WO2022078279A1 (zh) 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
AU2021359457A1 (en) 2020-10-12 2023-05-11 Systimmune, Inc. Camptothecin derivative and its ligand-drug conjugate
EP4227309A4 (en) 2020-10-12 2024-11-27 Sichuan Baili Pharmaceutical Co. Ltd. DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
WO2022099762A1 (zh) 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
CN114569739A (zh) 2020-12-01 2022-06-03 正大天晴药业集团股份有限公司 抗体药物偶联物
WO2022133722A1 (zh) 2020-12-22 2022-06-30 宁波长阳科技股份有限公司 聚酰亚胺材料及其制备方法和应用
KR20230147092A (ko) * 2021-01-22 2023-10-20 바이원큐어 테라퓨틱스, 인크. 항-her-2/trop-2 작제물 및 이의 용도
AU2021423664B2 (en) 2021-01-28 2026-02-05 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
MX2023008716A (es) 2021-02-05 2023-08-02 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo.
KR102942648B1 (ko) 2021-02-09 2026-03-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 결합 장치 및 결합 화합물을 생성하는 방법
WO2022170676A1 (en) 2021-02-09 2022-08-18 Genequantum Healthcare (Suzhou) Co., Ltd. Conjugation device and method for producing conjugates
EP4304661A1 (en) 2021-03-08 2024-01-17 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
CN117042806A (zh) 2021-03-08 2023-11-10 启德医药科技（苏州）有限公司 抗体-免疫激动剂缀合物及其应用
AU2022259314A1 (en) 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
GB2605957B (en) 2021-04-14 2025-02-05 Yara Uk Ltd Seed coating composition comprising an organic acid
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
IL308246A (en) 2021-05-07 2024-01-01 Alx Oncology Inc Exataxane derivatives and antibody-drug conjugates thereof
CN115429893A (zh) 2021-06-02 2022-12-06 百奥泰生物制药股份有限公司 药物偶联物及其用途
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118591544A (zh) 2022-01-28 2024-09-03 博瑞生物医药（苏州）股份有限公司 用于制备抗体药物偶联物的连接子、化合物及用途
WO2023143319A1 (zh) 2022-01-28 2023-08-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
KR20250068592A (ko) * 2022-06-28 2025-05-16 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-fgfr3 항체 접합체 및 이의 의학적 용도
EP4554956A1 (en) 2022-07-15 2025-05-21 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof

Also Published As

Publication number Publication date
IL318296A (en) 2025-03-01
US20250064953A1 (en) 2025-02-27
JP2025524725A (ja) 2025-07-30
CN118251241A (zh) 2024-06-25
WO2024012566A9 (en) 2024-04-11
MX2025000590A (es) 2025-06-02
WO2024012566A2 (en) 2024-01-18
WO2024012566A3 (en) 2024-03-14
CN119462943A (zh) 2025-02-18
US12539336B2 (en) 2026-02-03
CA3262069A1 (en) 2024-01-18
EP4554626A2 (en) 2025-05-21
AU2023306440A1 (en) 2025-01-30
KR20250075560A (ko) 2025-05-28
CN118251241B (zh) 2024-12-13
MA71455A (fr) 2025-04-30

Similar Documents

Publication Publication Date Title
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20240086A1 (es) Anticuerpos anti-cd122 y usos de estos
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
AR129991A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
ZA202500116B (en) Anti-cldn18.2 antibody, and pharmaceutical composition and use thereof
CL2024002975A1 (es) Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
PE20260258A1 (es) Conjugados de ligando-farmaco citotoxico y usos farmaceuticos de estos
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
AR132376A1 (es) Conjugados de anticuerpo de steap2-fármaco y usos de los mismos
AR123728A1 (es) Anticuerpos cd1a y su uso
JP2024546759A5 (es)
AR125074A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
PE20240809A1 (es) Composiciones y metodos de los anticuerpos anti-pacap
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
AR121918A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
AR127270A1 (es) Formulación de anticuerpos anti-cd47
AR134368A1 (es) Anticuerpos anti-muc16 y usos de los mismos
AR130506A1 (es) Anticuerpos anti-lair1 humano
AR133427A1 (es) Anticuerpos anti-gprc5d y composiciones